Objective :
Evaluation of the market potential of the asset gained through the acquisition
Problem Statement:
A global pharmaceutical company wished to evaluate the market value of an asset obtained by acquiring a mid-cap company. The new class of drug showed the potential in targeting multiple tumors in combination with their in-house immune checkpoint inhibitor (CPI). The assessment formed the basis of their decision to either retain or divest the product later.
Our Methodology:
- Extensive Secondary Research
- Extensive Primary Research
- Competitive Benchmarking
- Clinical Trials Analysis
- Strategic Insights on Companies
- Forecasting
Results:
- Executive analysis, Information on therapy area, disease overview, unmet need, treatment algorithm, market drivers and barriers & SWOT analysis of the product/Indication
- Competitive landscape for marketed and pipeline products
- Detailed attribute analysis of the key competitor products
- Market size in terms of value and volume of marketed and pipeline products
- Detailed forecast for the acquired asset of interest and our final recommendation on investing/divesting
Our Related Services
Asset Prioritization
Develop R&D strategy with reliable analysis of your asset group and come up focused list of prioritized assets.
Market Assessment
Achieve Breakthroughs with all-encompassing Market Outlook Research
Sample Visuals
Transform your business with our case study. Download now and achieve your goals!
Related Insights
In-Licensing Opportunity
A large client based in USA, involved in drug delivery devices, with effective marketing and commercialization presence across the globe, wanted to in-license potential dMTS based drug delivery asset...
View CaseOut-Licensing Opportunity
A small pharmaceutical client based at Sweden, Europe with capabilities around a neonatal mesenchymal cells involved DelveInsight to identify a licensing partner for their stem cells product, from acr...
View CaseGo-To-Market Strategy
A medium pharmaceutical client based in United States with biosimilar commercial capabilities involved DelveInsight to identify commercial processes and strategies to launch their biosimilar in Europe...
View Case